Search

News Candesartan is beneficial in heart failure with mildly reduced ejection fraction

Analysis of data from the CHARM study showed that in patients with heart failure with mildly reduced ejection fraction (HFmrEF 0.40–0.49), candesartan compared to placebo reduces the risk of death from cardiovascular (CV) causes or hospitalization for heart failure similarly to patients with reduced ejection fraction (HFrEF < 0.40).

Source: Sartans in the Treatment of Hypertension 19. 4. 2021

News Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure

The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing worldwide, and the combination of both diseases significantly worsens the prognosis of patients. One of the main causes of increased mortality in these patients is macrovascular complications of DM2. The burden on the cardiovascular system is even greater with the concurrent occurrence of chronic heart failure.

Source: Heart Failure 25. 4. 2022

News Modern View on Schizophrenia Therapy Through the Lens of Lurasidone

At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia Diagnosis', which took place on October 18, 2021, in Prague, Professor of Psychiatry and Molecular Biology Christoph U. Correll from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell spoke. His lecture included insights on current approaches to schizophrenia therapy and key information on one of the newest antipsychotics -⁠ lurasidone.

Source: Modern Treatment of Schizophrenia 14. 12. 2021

News Lurasidone in the Treatment of Adolescent Schizophrenia: How Does It Compare with Other Atypical Antipsychotics?

A meta-analysis of 13 studies comparing lurasidone with other atypical antipsychotics in monotherapy for adolescent patients with schizophrenia evaluated the effectiveness of the treatment, the rate of weight gain, and the frequency of medication discontinuation for each modality.

Source: Modern Treatment of Schizophrenia 27. 9. 2022

News Improvement in social functioning of patients with schizophrenia during treatment with lurasidone

A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A recently published Japanese study is the first to demonstrate the efficacy of lurasidone compared to placebo on the social functioning of patients with schizophrenia. The results are comparable to other atypical antipsychotics.

Source: Modern Treatment of Schizophrenia 19. 3. 2024

News Case Study of a Patient with NSCLC −⁠ with Voting

Presented by: MUDr. Leona Koubková, Pneumology Clinic, 2nd Faculty of Medicine, Charles University and Motol University Hospital in Prague

Source: Immunotherapy in Oncology 5. 10. 2020

News Postpartum Uterine Artery Pseudoaneurysm in a Woman with vWD –⁠ Case Study

Women with von Willebrand disease (vWD) have a significantly higher risk of postpartum hemorrhage. American experts from University Hospital in Augusta have published their experience with an unusual case of secondary postpartum hemorrhage in a young woman with type 1 vWD.

Source: Von Willebrand Disease 28. 6. 2023

News Bone density in hemophiliacs −⁠ known and less-known risk factors

Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?

Source: Hemophilia 20. 8. 2022

News Does the choice of therapy for primary hypertension in patients with COVID-19 affect the severity of the disease?

The effect of two commonly used antihypertensives was evaluated in a randomized clinical trial in patients with primary hypertension and COVID-19.

Source: Sartans in the Treatment of Hypertension 24. 3. 2022

News Current Challenges in Diagnosing Progressive Fibrotic Interstitial Lung Diseases

A subset of patients with interstitial lung diseases exhibits a progressive fibrotic phenotype associated with a deterioration in quality of life and increased mortality. Early diagnosis and adequate therapy could improve their prognosis, but currently, there are numerous problems and challenges.

Source: Progressive Interstitial Pulmonary Processes 7. 9. 2022

News Can Empagliflozin Also Act Against Gout?

Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio -⁠ and renoprotective effects. It now appears that in type 2 diabetics, they may lower serum uric acid levels and help prevent the development of gout. This was suggested by a post hoc analysis of data from the EMPA-REG OUTCOME study in the case of empagliflozin.

Source: Diabetes 21. 7. 2023

News Study TACTIC –⁠ Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice

In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with trifluridine/tipiracil (FTD/TPI) was associated with improved overall survival and progression-free survival in pre-treated metastatic colorectal cancer (mCRC) patients. The below-presented TACTIC study provides prospective data from German real-world practice.

Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A

Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.

Source: Hemophilia 20. 2. 2023

News Tailored Treatment. Who is Teriflunomide Suitable For?

The authors of the recently published study cited below not only focused on the safety and efficacy of teriflunomide in real-world clinical practice but also on the risk factors for its insufficient effectiveness. Who is teriflunomide most suitable for, and when should alternatives be considered?

Source: Multiple Sclerosis 3. 11. 2022

News Cognitive changes in MS –⁠ what can teriflunomide do?

In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?

Source: Multiple Sclerosis 10. 10. 2022